11th International AIDS Conference Vancouver, British Columbia — July 7-12, 1996

Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. LB.B.6041)
Hsu A, Granneman GR, Sun E, Chen P, El-Shourbagy T, Locke C, Baroldi P, Carothers L, Cao G, Qian J, Pizzuti D, Stewart F, Leonard J; Abbott Laboratories, Abbott Park, IL. Fax: (847) 938-5193. E-mail: Ann.Hsu@abbott.com.

STUDY DESIGN: Two interaction studies have been conducted in healthy, non-HIV female and male volunteers using Norvir capsules and Invirase capsules under nonfasting conditions. The single-dose study involved 6 dose groups utilizing a crossover design and the 2-week multiple-dose study involved five parallel dose groups.

RESULTS: Consistent with the fact that ritonavir (R) is a potent cytochrome P450 3A inhibitor, saquinavir (S) plasma concentrations were profoundly increased when coadministered with ritonavir, while ritonavir pharmacokinetics were practically not affected with coadministration of saquinavir. (Table: see text) All dose regimens were well-tolerated. Adverse events and laboratory abnormalities observed, primarily circumoral paresthesia, nausea, asthenia, and elevated triglyceride levels, were generally mild in nature.

960707
LBB6041

Copyright © 1996 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.